Johnson & Johnson (JNJ)
155.50
+2.39
(+1.56%)
USD |
NYSE |
Nov 21, 16:00
155.43
-0.07
(-0.05%)
After-Hours: 20:00
Johnson & Johnson Enterprise Value: 384.09B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 384.09B |
| November 19, 2024 | 383.82B |
| November 18, 2024 | 388.08B |
| November 15, 2024 | 386.23B |
| November 14, 2024 | 381.10B |
| November 13, 2024 | 384.40B |
| November 12, 2024 | 382.95B |
| November 11, 2024 | 388.73B |
| November 08, 2024 | 389.77B |
| November 07, 2024 | 392.80B |
| November 06, 2024 | 395.57B |
| November 05, 2024 | 396.70B |
| November 04, 2024 | 396.44B |
| November 01, 2024 | 400.99B |
| October 31, 2024 | 400.34B |
| October 30, 2024 | 402.14B |
| October 29, 2024 | 400.89B |
| October 28, 2024 | 404.53B |
| October 25, 2024 | 402.79B |
| October 24, 2024 | 409.51B |
| October 23, 2024 | 414.78B |
| October 22, 2024 | 408.98B |
| October 21, 2024 | 407.49B |
| October 18, 2024 | 413.00B |
| October 17, 2024 | 411.44B |
| Date | Value |
|---|---|
| October 16, 2024 | 410.98B |
| October 15, 2024 | 410.49B |
| October 14, 2024 | 404.47B |
| October 11, 2024 | 404.14B |
| October 10, 2024 | 401.85B |
| October 09, 2024 | 402.19B |
| October 08, 2024 | 399.88B |
| October 07, 2024 | 399.49B |
| October 04, 2024 | 401.32B |
| October 03, 2024 | 401.83B |
| October 02, 2024 | 403.44B |
| October 01, 2024 | 405.41B |
| September 30, 2024 | 405.58B |
| September 27, 2024 | 404.55B |
| September 26, 2024 | 404.52B |
| September 25, 2024 | 402.62B |
| September 24, 2024 | 407.87B |
| September 23, 2024 | 408.93B |
| September 20, 2024 | 411.19B |
| September 19, 2024 | 412.78B |
| September 18, 2024 | 415.98B |
| September 17, 2024 | 418.19B |
| September 16, 2024 | 418.00B |
| September 13, 2024 | 414.46B |
| September 12, 2024 | 412.34B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
301.41B
Minimum
Mar 23 2020
492.23B
Maximum
Apr 25 2022
420.05B
Average
422.03B
Median
Enterprise Value Benchmarks
| Amgen Inc | 206.13B |
| Eli Lilly and Co | 742.91B |
| Merck & Co Inc | 270.08B |
| Pfizer Inc | 198.27B |
| AbbVie Inc | 360.29B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.694B |
| Revenue (Quarterly) | 22.47B |
| Total Expenses (Quarterly) | 17.19B |
| EPS Diluted (Quarterly) | 1.11 |
| Gross Profit Margin (Quarterly) | 69.01% |
| Profit Margin (Quarterly) | 11.99% |
| Earnings Yield | 3.89% |
| Operating Earnings Yield | 6.04% |
| Normalized Earnings Yield | 5.484 |